MEDNAX (MD) Tops Q4 EPS by 8c; Issues 2022 EBITDA Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St futures rise on tech buying, Middle East peace hopes
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil falls as traders digest escalation in US-Iran strikes
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
- UBS sees generational semiconductor boom, highlights stock winners
Mednax Reports Fourth Quarter Results
February 17, 2022 6:00 AM ESTFORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- Mednax, Inc. (NYSE: MD), and its affiliated practices operating as Pediatrix® Medical Group, the nations leading provider of highly specialized health care for women, children and babies, today reported earnings from continuing operations of $0.47 per share for the three months ended December 31, 2021. On a non-GAAP basis, Mednax reported Adjusted EPS from continuing operations of $0.52.
For the 2021 fourth quarter, Mednax reported the following results from continuing operations:
Net revenue of $499 million; Income from continuing operations of $68 million;... More